|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,038.50 DKK | +0.32% |
|
+0.05% | +36.95% |
| 08:03am | Genmab announces data from multiple clinical trials | RE |
| 08:03am | Genmab presents phase 3 data from EPCORE FL-1 trial | RE |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 19.5B | |||||
| 54.89B | |||||
| 43.51B | - | ||||
| 38.12B | |||||
| 23.14B | - | ||||
| 17.25B |
- Stock Market
- Equities
- GMAB Stock
- Charts Genmab A/S
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition